4Newlands ES, Bagshawe KD, Begent RH, et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol, 1991,98:550-557.
5Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol,2000,18:854-859.
6Randall TC, Coukos G, Wheeler JE, et al. Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. Gynecol Oncol, 2000, 76:115-117.
7Lurain JR. Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med, 2002, 47:451-459.
8Af-Sarrnf M, Fehfnme M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase Ⅲ randomize of intergroup study 0099 [J]. J Clin Oncol,1998,16:1310.
9Ali H, Al-Sarraf M. Chemotherapy in advanced nasopharyngeal cancer [J]. Oncology,2000,14(8):1223-1230.
10Kohno N, Ikari T, Kawaida M, et al. Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck [J] .Jpn J Clin Oncol,2000,30(6):253-258.
